HBO Kennisbank

4 Resultaten

Sorteer op:

Zocht je misschien: tony, tone?

Feasibility Study to Assess Canagliflozin Distribution and Sodium-Glucose Co-Transporter 2 Occupancy Using [18F]Canagliflozin in Patients with Type 2 Diabetes

van der Hoek, Sjoukje; Willemsen, Antoon T.M.; Visser, Ton; Heeres, Andre (Biobased Chemistry & Refinery); Mulder, Douwe J.; Bokkers, Reinoud P.H.; Slart, Riemer H.J.A.; Elsinga, Philip H.; Heerspink, Hiddo J.L.; Stevens, Jasper

Sodium-glucose co-transporter 2 (SGLT2) inhibitors, including canagliflozin, reduce the risk of cardiovascular and kidney outcomes in patients with and without type 2 diabetes, albeit with a large interindividual variation. The underlying mechanisms for this variation in response might be attributed …

2023-03-10AlgemeenArtikel

Studying Telmisartan Plasma Exposure, Kidney Distribution, Receptor Occupancy, and Response in Patients With Type 2 Diabetes Using [11C]Telmisartan

van der Hoek, Sjoukje; Mulder, Douwe J.; T.M. Willemsen, Antoon; Visser, Ton J.; Heeres, André (Biobased Chemistry & Refinery); Slart, Riemer H.J.A.; Elsinga, Philip H.; Heerspink, Hiddo J. L.; Stevens, Jasper

The angiotensin receptor blocker telmisartan slows progression of kidney disease in patients with type 2 diabetes (T2D), yet many patients remain at high risk for progressive kidney function loss. The underlying mechanisms for this response variation might be attributed to differences in angiotensin-1 …

2022-09-07AlgemeenArtikel

GMP Compliant Synthesis of Canagliflozin, a Novel PET Tracer for the Sodium−Glucose Cotransporter 2

Heeres, André (Biobased Chemistry & Refinery); van der Hoek, Sjoukje; Antunes, Inês F.; Attia, Khaled A.; Jacquet, Olivier; Bulthuis, Marian; Zijlma, Rolf; Boersma, Hendrikus H.; van Goor, Harry; Visser, Ton J.; Heerspink, Hiddo J. L.; Elsinga, Philip H.; Stevens, Jasper

Inhibition of the sodium−glucose cotransporter 2 (SGLT2) by canagliflozin in type 2 diabetes mellitus results in large between-patient variability in clinical response. To better understand this variability, the positron emission tomography (PET) tracer [18F]canagliflozin was developed via a Cu-mediated …

2021-11-08AlgemeenArtikel

GMP Compliant Synthesis of [18F]Canagliflozin, a Novel PET Tracer for the Sodium−Glucose Cotransporter 2

van der Hoek, Sjoukje; Antunes, Inês F.; Attia, Khaled A.; Jacquet, Olivier; Heeres, André (Biobased Chemistry & Refinery); Bulthuis, Marian; Zijlma, Rolf; Boersma, Hendrikus H.; van Goor, Harry; Visser, Ton J.; Heerspink, Hiddo J. L.; Elsinga, Philip H.; Stevens, Jasper

Inhibition of the sodium–glucose cotransporter 2 (SGLT2) by canagliflozin in type 2 diabetes mellitus results in large between-patient variability in clinical response. To better understand this variability, the positron emission tomography (PET) tracer [18F]canagliflozin was developed via a Cu-mediated …

2021-11-08AlgemeenArtikel

Vorige Volgende

Feasibility Study to Assess Canagliflozin Distribution and Sodium-Glucose Co-Transporter 2 Occupancy Using [18F]Canagliflozin in Patients with Type 2 Diabetes

Studying Telmisartan Plasma Exposure, Kidney Distribution, Receptor Occupancy, and Response in Patients With Type 2 Diabetes Using [11C]Telmisartan

GMP Compliant Synthesis of Canagliflozin, a Novel PET Tracer for the Sodium−Glucose Cotransporter 2

GMP Compliant Synthesis of [18F]Canagliflozin, a Novel PET Tracer for the Sodium−Glucose Cotransporter 2

Over HBO Kennisbank